IPP Bureau
Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet
By IPP Bureau - January 16, 2026
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
By IPP Bureau - January 16, 2026
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Zydus receives final approval from USFDA for Eltrombopag Tablets
By IPP Bureau - January 16, 2026
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment
By IPP Bureau - January 16, 2026
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Vetter advances next-gen syringe closure system towards 2027 launch
By IPP Bureau - January 16, 2026
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
Avantium and Packamama join forces to revolutionise wine packaging with plant-based polymer
By IPP Bureau - January 16, 2026
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
Bayer acquires Attralus’ cardiac amyloidosis imaging agents
By IPP Bureau - January 16, 2026
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
FDA finds no clear link between popular diabetes, weight-loss drugs and suicidal thoughts
By IPP Bureau - January 16, 2026
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
EMA and FDA unveil joint AI principles to transform drug revelopment
By IPP Bureau - January 16, 2026
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Biocon completes Rs. 4,150 crore equity fundraise through QIP
By IPP Bureau - January 15, 2026
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Max Healthcare teams up with Google to enable direct appointment bookings
By IPP Bureau - January 15, 2026
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
Vivere Oncotherapies secures more than $10M to tackle hard-to-treat ‘cold’ tumors
By IPP Bureau - January 15, 2026
BioNTech maps pivotal oncology milestones for 2026
By IPP Bureau - January 15, 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
